AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

By Yahoo! Finance | Nov 16, 2024 at 02:08 AM EST

AIM ImmunoTech is focusing on reducing Ampligen production costs through manufacturing efficiencies. Progress is positive in pancreatic cancer trials, moving to Phase II soon. The ovarian cancer trial is downsizing due to impressive response rates. Financial challenges include disputes over accounts payable and insurance coverage.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.